Abstract
Despite the introduction of effective, novel agents, the outcome of patients with refractory multiple myeloma remains poor, particularly those who are refractory to both proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs). Limited data are available on the role of autologous hematopoietic stem cell transplantation in this population. Patients with refractory myeloma who underwent first autologous hematopoietic stem cell transplantation (auto-HCT) between March 2000 and October 2015 were retrospectively analyzed. Those who had primary refractory disease and those with relapsed and refractory disease were included. Disease that was refractory to at least 1 PI and at least 1 IMiD was classified as double-refractory multiple myeloma (DR-MM). In total, 233 patients were identified, including 105 (45%) classified with DR-MM and 128 (55%) classified with nondouble-refractory myeloma (NDR-MM). At a median follow-up of 42 months for surviving patients, at least a partial response was observed in 188 patients (81%; 83 patients in the DR-MM group [79%] and 105 patients in the NDR-MM [82%]; P = .77). A near complete response or better was observed in 52 patients (22%; 25 patients in the DR-MM group [24%] and 27 patients in the ...Continue Reading
References
Sep 1, 1994·British Journal of Haematology·J BladéC Rozman
Dec 16, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Mar 3, 1999·European Journal of Haematology·T M OivanenI Palva
Nov 7, 2002·Bone Marrow Transplantation·S SinghalJ Mehta
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Choon-Kee LeeGuido Tricot
Oct 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Craig T Wallington-BeddoeMary M Sartor
Jan 22, 2010·Blood·Morie A GertzWilliam J Hogan
Feb 16, 2010·Bone Marrow Transplantation·D TanW Hwang
Nov 26, 2010·Blood·Philippe MoreauUNKNOWN IFM 2005-01 study investigators
Feb 5, 2011·Blood·S Vincent RajkumarUNKNOWN International Myeloma Workshop Consensus Panel 1
Jul 30, 2011·Leukemia·S K KumarUNKNOWN International Myeloma Working Group
Nov 8, 2011·Haematologica·Laura RosiñolUNKNOWN PETHEMA/Spanish Myeloma Group
Oct 3, 2013·Annals of Hematology·Sung-Eun LeeChang-Ki Min
Sep 23, 2014·The Lancet Oncology·Jesús F San-MiguelPaul G Richardson
Dec 3, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ravi VijParameswaran N Hari
Jun 3, 2015·The New England Journal of Medicine·Sagar LonialUNKNOWN ELOQUENT-2 Investigators
Jul 28, 2015·American Journal of Hematology·Neil MajithiaShaji K Kumar
Sep 13, 2015·Clinical Lymphoma, Myeloma & Leukemia·Syed M KazmiQaiser Bashir
Dec 17, 2015·The Lancet Oncology·Meletios A DimopoulosUNKNOWN ENDEAVOR Investigators
Aug 4, 2016·The Oncologist·Saad UsmaniManeesha Mehra
Aug 9, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Emma C ScottAnita D'Souza
Aug 25, 2016·The New England Journal of Medicine·Antonio PalumboUNKNOWN CASTOR Investigators
Oct 6, 2016·The New England Journal of Medicine·Meletios A DimopoulosUNKNOWN POLLUX Investigators
Citations
Jul 7, 2020·Leukemia & Lymphoma·Artur JurczyszynAjay K Nooka
Jul 28, 2018·Journal of Immunology Research·Yanhua ZhengGuangxun Gao
Jun 10, 2020·Hematology/oncology and Stem Cell Therapy·Mohammad Abdurrehman SheikhShahrukh K Hashmi